Stockreport

Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001 [Yahoo! Finance...

Alzamend Neuro, Inc.  (ALZN) 
PDF Safety aspects of AL001 development may qualify for a 505(b)(2) NDA pathway for FDA approval ATLANTA, November 13, 2023 BUSINESS WIRE Alzamend Neuro, Inc. (Nasdaq: AL [Read more]